The post Support Groups with Cleo Dougherty appeared first on UCI MIND.
더 읽어보기
The post 34th Annual Southern California Alzheimer’s Disease Research Conference appeared first on UCI MIND.
더 읽어보기
July 6, 2023—Today, the US Food and Drug Administration granted full approval to the drug lecanemab (brand name Leqembi®), a monoclonal antibody that has been demonstrated to lower levels of…
더 읽어보기
On June 9, The US Food and Drug Administration convened members of the updated Peripheral and Central Nervous System Drugs Advisory Committee to review the available data for lecanemab, the monoclonal…
더 읽어보기
UCI MIND Director, Dr. Joshua Grill, named one of this year’s OC50 (50 people shaping the future of healthcare in Orange County) in the Orange County Business Journal. Read the…
더 읽어보기
Masashi Kitazawa, Associate Professor of Environmental and Occupational Health, and his team found exposure to traffic-related air pollution led to memory loss and cognitive decline and triggered neurological pathways associated…
더 읽어보기
May 12, 2023–Brexpiprazole has now been approved by the FDA for the treatment of agitation in Alzheimer’s dementia. Agitated behaviors are common in those with moderate or advanced Alzheimer’s dementia…
더 읽어보기
May 3, 2023–Eli Lilly and company announced today (https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional) the positive topline results from their Phase 3 clinical trial of donanemab, a monoclonal antibody that rapidly lowers beta amyloid levels…
더 읽어보기